Cellino
Founded Year
2017Stage
Series A | AliveTotal Raised
$100MLast Raised
$80M | 2 yrs agoAbout Cellino
Cellino develops an intracellular delivery technique for gene editing applications. The company provides stem cell-derived regenerative medicines that are poised to cure tough diseases, including Parkinson’s, diabetes, and heart disease. It combines label-free imaging and laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format. It was founded in 2017 and is based in Cambridge, Massachusetts.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Research containing Cellino
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Cellino in 1 CB Insights research brief, most recently on Nov 10, 2022.
Expert Collections containing Cellino
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cellino is included in 2 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,728 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Early-Stage Pharma Market Map
82 items
Cellino Patents
Cellino has filed 14 patents.
The 3 most popular patent topics include:
- Biotechnology
- Molecular biology
- Cell biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/7/2022 | 7/25/2023 | Biotechnology, Cell culture, Cell biology, Drug discovery, Molecular biology | Grant |
Application Date | 3/7/2022 |
|---|---|
Grant Date | 7/25/2023 |
Title | |
Related Topics | Biotechnology, Cell culture, Cell biology, Drug discovery, Molecular biology |
Status | Grant |
Latest Cellino News
May 17, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #democratization--Cellino Biotech, Inc., the cell therapy biomanufacturing company unlocking personalized regenerative medicine at scale, has been named the winner of the “Scalable Solutions'' category of the Advanced Research Projects Agency for Health’s (“ARPA-H”) inaugural Dash to Accelerate Health Outcomes. Cellino was also named overall first runner-up out of 64 teams after six rounds of voting. ARPA-H is a research funding agency born out of the White House’s pledge to su
Cellino Frequently Asked Questions (FAQ)
When was Cellino founded?
Cellino was founded in 2017.
Where is Cellino's headquarters?
Cellino's headquarters is located at 750 Main Street, Cambridge.
What is Cellino's latest funding round?
Cellino's latest funding round is Series A.
How much did Cellino raise?
Cellino raised a total of $100M.
Who are the investors of Cellino?
Investors of Cellino include 8VC, The Engine, Humboldt Fund, Khosla Ventures, Felicis and 5 more.
Who are Cellino's competitors?
Competitors of Cellino include Multiply Labs.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Cellino to Competitors
Ori Biotech develops a proprietary, flexible manufacturing platform. It closes, automates, and standardizes manufacturing, allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company was founded in 2015 and is based in London, United Kingdom.
Cellares provides a cell therapy manufacturing technology platform. It focuses on Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing. It was founded in 2019 and is based in South San Francisco, California.
OneFul personalizes multi-drug chronic therapies formulated using digital health data, combining 3-7 prescriptions of individually dosed high-potency drugs. It seeks to improve the quality of life for millions of patients with affordable personalized medicine that are much easier to take. It delivers multiple drugs combined for a person, as prescribed by the doctor from its modern OneFul Pharmacies by using precision medicine science and made with robotic accuracy. It was founded in 2013 and is based in Durham, North Carolina.
Multiply Labs builds robotic devices to produce customized medications. It manufactures cloud-controlled robotic systems enabling the production of individualized drugs at scale. Multiply Labs was formerly known as Pharmacube. The company was founded in 2016 and is based in San Fransico, California.
Equashield provides automated solutions to protect healthcare workers and facilities from the risks associated with hazardous drug exposure and contamination. The company offers closed-back syringes and automated compounding robots to optimize the daily ability to safety. It was founded in 2009 and is based in Port Washington, New York.
Panaceutics is a personalized medicine and clinical nutrition company. Panaceutics delivers personalized monthly subscriptions of "pill free" suspensions combining up to 20 active ingredients in tasty puree filled pouches that are a convenient way to take individualized formulas of clinical nutrition and pharmacy grade dietary supplements. Cloud-based software is used to choose the right ingredients and dosage for an individual, and the formula is then sent to Panaceutics' proprietary robotic system that builds a 30-day supply in less than 4 minutes under cGMP quality rules. The company was founded in 2018 and is based in Ringgold, Virginia.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
